December 20, 2019

Immunotech s.r.o.   
Vit Oburka   
Quality and Regulatory Affairs Manager Radiova 1   
Prague, 102 27 Cz

Re: K191350 Trade/Device Name: ACTIVE $\textsuperscript { \textregistered }$ Free Testosterone RIA Regulation Number: 21 CFR 862.1680 Regulation Name: Testosterone Test System Regulatory Class: Class I, reserved Product Code: CDZ Dated: November 25, 2019 Received: November 25, 2019

Dear Vit Oburka:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531- 542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical  
devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn   
(https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Marianela Perez-Torres, Ph.D.   
Acting Deputy Director   
Division of Chemistry and Toxicology Devices   
OHT7: Office of In Vitro Diagnostics and Radiological Health   
Office of Product Evaluation and Quality   
Center for Devices and Radiological Health

Enclosure

510(k) Number (if known) K191350

Device Name ACTIVE $\textsuperscript { \textregistered }$ Free Testosterone RIA

Indications for Use (Describe)   
Radioimmunoassay for the quantitative measurement of free testosterone in human serum. This assay is intended for in vitro diagnostic use.

Free testosterone test is used in the diagnosis and treatment of disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, delayed or precocious puberty, impotence in males and, in female’s hirsutism (excessive hair) and virilization (masculinization) due to tumors, polycystic ovaries, and adrenogenital syndromes.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”

# 510k Summary ACTIVE $\textcircled{8}$ Free Testosterone RIA

# 1. Submitted by:

Vit Oburka   
Quality and Regulatory Affairs Manager IMMUNOTECH s.r.o.   
Radiova 1,   
102 27 Prague   
Czech Republic   
Tel.: $\yen 420$ 272 017 368   
Email: voburka@beckman.com

# 2. Date of preparation:

October 19, 2019

# 3. Device Identification

Proprietary Name: ACTIVE $\textsuperscript { \textregistered }$ Free Testosterone RIA Common Name: Free Testosterone Classification: Class I, reserved Product Codes: CDZ Regulation Number: 21 CFR 862.1680

# 4. Predicate Device

<table><tr><td rowspan=1 colspan=1>Proposed Device</td><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>Manufacturer</td><td rowspan=1 colspan=1>LicenseNumber</td></tr><tr><td rowspan=1 colspan=1>ACTIVE® FreeTestosterone RIA</td><td rowspan=1 colspan=1>ACTIVE® FreeTestosterone RIA</td><td rowspan=1 colspan=1>IMMUNOTECH s.r.0.</td><td rowspan=1 colspan=1>K952281</td></tr></table>

# 5. Description

Kit Content: Free Testosterone Antibody-Coated Tubes: $\mathbf { 2 \times 5 0 }$ tubes (ready-to-use)

Plastic tubes with rabbit anti-testosterone immunoglobulin immobilized to the inside wall of each tube.

125I-labeled Testosterone Analog Tracer (YELLOW): one ${ \bf 2 2 m L }$ vial (ready-to-use) At the time of manufacture, the vial contains $1 8 5 \mathsf { k B q }$ , $( < 5 \mu \mathsf { C i } )$ , of $^ { 1 2 5 } |$ -labeled testosterone analog in buffer with proteins (BSA), sodium azide $( < 0 . 1 \% )$ and a dye.

Calibrators: one $1 . 0 \ \mathrm { m L }$ vial labeled 0, and seven $0 . 5 ~ \mathsf { m L }$ vials labeled 1-7 (ready-touse)

The calibrator vials contain from 0 to approximately $1 0 0 ~ \mathsf { p g / m L }$ (0 to approximately 346.7 pmol/L) of free testosterone in human serum with sodium azide $( < 0 . 1 \% )$ . The exact concentration is indicated on each vial label. Once opened, store at $2 . 8 ^ { \circ } \mathsf { C }$ for up to 3 weeks, or at $\angle \cdot 2 0 ^ { \circ } \mathrm { C }$ until expiration date of kit. The calibrator values were established using an internal standard.

Controls: two $\pmb { 0 . 5 } \pmb { \mathrm { m L } }$ vials labeled 1, 2 (ready-to-use)

The vials contain free testosterone in human serum with sodium azide $( < 0 . 1 \% )$ . The expected values are in the concentration range indicated in a supplement found in the kit. Once opened, store at ${ 2 / 8 ^ { \circ } \mathsf { C } }$ for up to 3 weeks, or at $\angle - 2 0 ^ { \circ } \mathrm { C }$ until expiration date of kit.

# Principle

The radioimmunoassay of free testosterone is a competitive assay. The procedure follows the basic principle of radioimmunoassay where there is competition between a radioactive and a non-radioactive antigen for a mixed number of antibody binding sites. The amount of [125I]-labeled testosterone analog bound to the antibody is inversely proportional to the concentration of unlabeled free testosterone present. The separation of the free and bound antigen is achieved by decanting or aspirating the antibody-coated tubes. A standard curve is constructed and unknown free testosterone values are obtained from the curve by interpolation.

# 6. Intended use:

Radioimmunoassay for the quantitative measurement of free testosterone in human serum. This assay is intended for in vitro diagnostic use.

Free testosterone test is used in the diagnosis and treatment of disorders involving the male sex hormones (androgens), including primary and secondary hypogonadism, delayed or precocious puberty, impotence in males and, in female’s hirsutism (excessive hair) and virilization (masculinization) due to tumors, polycystic ovaries, and adrenogenital syndromes.

# Clinical Significance:

Free Testosterone is often measured in conjunction with other androgens (DHEA/DHEAS, androstenedione, 17α-hydroxyprogesterone), SHBG and gonadotropins (LH and FSH) to evaluate reproductive abnormalities in children, men and women.

# 7. Comparison to Predicate(s):

The following tables shows similarities and differences between the predicate identified in Section 4. of this summary.

Similarities between the Predicate Device and the Proposed Device:

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Predicate</td><td colspan="1" rowspan="1">Proposed Device</td></tr><tr><td colspan="1" rowspan="1">Proprietary andEstablishedNames</td><td colspan="1" rowspan="1">ACTIVE® Free TestosteroneRIA</td><td colspan="1" rowspan="1">ACTIVE ® Free TestosteroneRIA</td></tr><tr><td colspan="1" rowspan="1">Antibody</td><td colspan="1" rowspan="1">Polyclonal RabbitTestosterone Antiserum,A140, DSL</td><td colspan="1" rowspan="1">Polyclonal RabbitTestosterone Antibody, 20-TR05T, Fitzgerald</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">SameRadioimmunoassay for thequantitative measurement offree testosterone in humanserum. This assay is intendedfor in vitro diagnostic use.</td><td colspan="1" rowspan="1">SameRadioimmunoassay for thequantitative measurement offree testosterone in humanserum. This assay is intendedfor in vitro diagnostic use.</td></tr><tr><td colspan="1" rowspan="1">Principal</td><td colspan="2" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Warning andPrecautions</td><td colspan="2" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">MaterialsProvided</td><td colspan="2" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Materialsrequired, but notprovided</td><td colspan="2" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Specimencollection,processing,</td><td colspan="2" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">storage anddilution</td><td colspan="1" rowspan="1">EY</td></tr><tr><td colspan="1" rowspan="1">Procedure</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Quality Control</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Packaging</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Stability</td><td colspan="1" rowspan="1">Same</td></tr></table>

These are the study results from the validation and verification activities conducted to support the change in polyclonal antibody.

Information describing new proposed assay:

<table><tr><td>IFU Claim</td></tr><tr><td>Expected Values Claim expansion through stratification</td></tr></table>

<table><tr><td rowspan=1 colspan=1>IFU Claim</td><td rowspan=1 colspan=9>Proposed Device</td></tr><tr><td rowspan=7 colspan=2>ExpectedValuesClaimexpansionthroughstratification</td><td rowspan=1 colspan=8>Each laboratory should establish its own reference ranges.</td></tr><tr><td rowspan=1 colspan=1>Men (agein years)</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Median(pg/mL)</td><td rowspan=1 colspan=1>Min(pg/mL)</td><td rowspan=1 colspan=1>Max(pg/mL)</td><td rowspan=1 colspan=1>2.5thPercentile(pg/mL)</td><td rowspan=1 colspan=1>97.5thPercentile(pg/mL)</td><td rowspan=6 colspan=1></td></tr><tr><td rowspan=1 colspan=1>20-29</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>15.40</td><td rowspan=1 colspan=1>7.54</td><td rowspan=1 colspan=1>27.79</td><td rowspan=1 colspan=1>8.68</td><td rowspan=1 colspan=1>25.09</td></tr><tr><td rowspan=1 colspan=1>30-39</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>14.94</td><td rowspan=1 colspan=1>6.77</td><td rowspan=1 colspan=1>22.36</td><td rowspan=1 colspan=1>8.85</td><td rowspan=1 colspan=1>21.40</td></tr><tr><td rowspan=1 colspan=1>40-49</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>11.48</td><td rowspan=1 colspan=1>7.37</td><td rowspan=1 colspan=1>20.47</td><td rowspan=1 colspan=1>7.56</td><td rowspan=1 colspan=1>18.64</td></tr><tr><td rowspan=1 colspan=1>50 andabove</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>9.05</td><td rowspan=1 colspan=1>4.52</td><td rowspan=1 colspan=1>15.05</td><td rowspan=1 colspan=1>5.72</td><td rowspan=1 colspan=1>14.21</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>12.35</td><td rowspan=1 colspan=1>4.52</td><td rowspan=1 colspan=1>27.79</td><td rowspan=1 colspan=1>6.76</td><td rowspan=1 colspan=1>22.76</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Women</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Median(pg/mL)</td><td rowspan=1 colspan=1>Min(pg/mL)</td><td rowspan=1 colspan=1>Max(pg/mL)</td><td rowspan=1 colspan=1>2.5thPercentile (pg/mL)</td><td rowspan=1 colspan=1>97.5thPercentile(pg/mL)</td></tr><tr><td rowspan=1 colspan=1>FollicularPhase</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>1.48</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>4.28</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>3.41</td></tr><tr><td rowspan=1 colspan=1>LutealPhase</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>1.44</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>3.31</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>2.95</td></tr><tr><td rowspan=1 colspan=1>Preovulatory Peak</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>1.51</td><td rowspan=1 colspan=1>0.81</td><td rowspan=1 colspan=1>3.79</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>3.79</td></tr><tr><td rowspan=1 colspan=1>Postmenopausal</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>1.17</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>1.97</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>1.85</td></tr><tr><td rowspan=1 colspan=1>Contraceptives</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1.45</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>2.81</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>2.70</td></tr></table>

<table><tr><td rowspan=1 colspan=1>RandomWomen</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Median(pg/mL)</td><td rowspan=1 colspan=1>Min(pg/mL)</td><td rowspan=1 colspan=1>Max(pg/mL)</td><td rowspan=1 colspan=1>2.5thPercentile (pg/mL)</td><td rowspan=1 colspan=1>97.5thPercentile(pg/mL)</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>1.29</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>4.28</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>2.87</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Boys</td><td colspan="1" rowspan="1">n</td><td colspan="1" rowspan="1">Median(pg/mL)</td><td colspan="1" rowspan="1">Min(pg/mL)</td><td colspan="1" rowspan="1">Max(pg/mL)</td><td colspan="1" rowspan="1">2.5thPercentile(pg/mL)</td><td colspan="1" rowspan="1">97.5thPercentile(pg/mL)</td></tr><tr><td colspan="1" rowspan="1">Infant</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">&lt; 0.13</td><td colspan="1" rowspan="1">&lt; 0.13</td><td colspan="1" rowspan="1">0.31</td><td colspan="1" rowspan="1">&lt; 0.13</td><td colspan="1" rowspan="1">0.28</td></tr><tr><td colspan="1" rowspan="1">Child</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">0.56</td><td colspan="1" rowspan="1">0.13</td><td colspan="1" rowspan="1">12.79</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">12.65</td></tr><tr><td colspan="1" rowspan="1">Adolescent</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">15.10</td><td colspan="1" rowspan="1">1.71</td><td colspan="1" rowspan="1">32.09</td><td colspan="1" rowspan="1">1.88</td><td colspan="1" rowspan="1">28.55</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Boys</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Median(pg/mL)</td><td rowspan=1 colspan=1>Minimum(pg/mL)</td><td rowspan=1 colspan=1>Maximum(pg/mL)</td><td rowspan=1 colspan=1>2.5thPercentile(pg/mL)</td><td rowspan=1 colspan=1>97.5thPercentile(pg/mL)</td></tr><tr><td rowspan=1 colspan=1>6 months-9 years</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>&lt;0.13</td><td rowspan=1 colspan=1>0.62</td><td rowspan=1 colspan=1>&lt;0.13</td><td rowspan=1 colspan=1>0.54</td></tr><tr><td rowspan=1 colspan=1>10-11years</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0.67</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>5.11</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>5.00</td></tr><tr><td rowspan=1 colspan=1>12-13years</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>6.21</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>27.21</td><td rowspan=1 colspan=1>0.63</td><td rowspan=1 colspan=1>23.27</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Girls</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Median(pg/mL)</td><td rowspan=1 colspan=1>Min(pg/mL)</td><td rowspan=1 colspan=1>Max(pg/mL)</td><td rowspan=1 colspan=1>2.5thPercentile(pg/mL)</td><td rowspan=1 colspan=1>97.5thPercentile(pg/mL)</td></tr><tr><td rowspan=1 colspan=1>Infant</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>&lt; 0.13</td><td rowspan=1 colspan=1>&lt; 0.13</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>&lt; 0.13</td><td rowspan=1 colspan=1>0.33</td></tr><tr><td rowspan=1 colspan=1>Child</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>0.46</td><td rowspan=1 colspan=1>&lt; 0.13</td><td rowspan=1 colspan=1>2.53</td><td rowspan=1 colspan=1>&lt; 0.13</td><td rowspan=1 colspan=1>1.90</td></tr><tr><td rowspan=1 colspan=1>Adolescent</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1.37</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>3.27</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>3.23</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Girls</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Median(pg/mL)</td><td rowspan=1 colspan=1>Minimum(pg/mL)</td><td rowspan=1 colspan=1>Maximum(pg/mL)</td><td rowspan=1 colspan=1>2.5thPercentile(pg/mL)</td><td rowspan=1 colspan=1>97.5thPercentile(pg/mL)</td></tr><tr><td rowspan=1 colspan=1>6 months-9years</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>&lt;0.13</td><td rowspan=1 colspan=1>0.86</td><td rowspan=1 colspan=1>&lt;0.13</td><td rowspan=1 colspan=1>0.57</td></tr><tr><td rowspan=1 colspan=1>10-12 years</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>2.53</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>2.25</td></tr><tr><td rowspan=1 colspan=1>13-16 years</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>3.27</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>3.24</td></tr></table>

<table><tr><td>Performance characteristic Measured according to CLSI guidelines</td><td>Sensitivity Limit of Blank (LoB) of 0.05 pg/mL. Limit of detection (LoD): 0.13 pg/mL Limit of Quantitation (LoQ): 0.37 pg/mL Specificity The antibody used in the immunoassay is highly specific for free</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="6" rowspan="1">PrecisionRepeatability and within-laboratory precisionFor repeatability the coefficients of variation werefound below or equal to 13.2% for serum samples. For within laboratoryprecision the coefficients of variation were found below or equal to 19.3% forserum samples.</td></tr><tr><td colspan="1" rowspan="1">Measurementrange</td><td colspan="6" rowspan="1">Measurement range (from LoQ to the highest calibrator): 0.37 pg/mL toapproximately 100 pg/mL</td></tr><tr><td colspan="1" rowspan="16">InterferenceNew dataCLSIguidelines</td><td colspan="6" rowspan="16">Substance                        Interferent concentrationHemoglobin                       641 μg/mLConjugated bilirubin              199 μg/mLUnconjugated bilirubin          92.7 μg/mLBiotin                               1,020 ng/mLAscorbic acid                     40.5 μg/mLIbuprofen                          122 μg/mLCholesterol                        0.75 mg/mLHeparin                            7,248 ng/mLPrednisone                       384 ng/mLPrednisolone                      1,294 ng/mLProtein (y-globulin)               49.5 mg/mLRheumatoid factor               3.45 IU/mLAcetylsalicylic acid               24.2 μg/mLTriglycerides                      3.35 mg/mL</td></tr><tr><td colspan="3" rowspan="1">Substance</td><td colspan="2" rowspan="1">Interferent concentration</td></tr><tr><td colspan="3" rowspan="1">Hemoglobin</td><td colspan="2" rowspan="1">641 μg/mL</td></tr><tr><td colspan="3" rowspan="1">Conjugated bilirubin</td><td colspan="2" rowspan="1">199 μg/mL</td></tr><tr><td colspan="3" rowspan="1">Unconjugated bilirubin</td><td colspan="2" rowspan="1">92.7 μg/mL</td></tr><tr><td colspan="3" rowspan="1">Biotin</td><td colspan="2" rowspan="1">1,020 ng/mL</td></tr><tr><td colspan="3" rowspan="1">Ascorbic acid</td><td colspan="2" rowspan="1">40.5 μg/mL</td></tr><tr><td colspan="3" rowspan="1">Ibuprofen</td><td colspan="2" rowspan="1">122 μg/mL</td></tr><tr><td colspan="3" rowspan="1">Cholesterol</td><td colspan="2" rowspan="1">0.75 mg/mL</td></tr><tr><td colspan="3" rowspan="1">Heparin</td><td colspan="2" rowspan="1">7,248 ng/mL</td></tr><tr><td colspan="3" rowspan="1">Prednisone</td><td colspan="2" rowspan="1">384 ng/mL</td></tr><tr><td colspan="3" rowspan="1">Prednisolone</td><td colspan="2" rowspan="1">1,294 ng/mL</td></tr><tr><td colspan="3" rowspan="1">Protein (y-globulin)</td><td colspan="2" rowspan="1">49.5 mg/mL</td></tr><tr><td colspan="3" rowspan="1">Rheumatoid factor</td><td colspan="2" rowspan="1">3.45 IU/mL</td></tr><tr><td colspan="3" rowspan="1">Acetylsalicylic acid</td><td colspan="2" rowspan="1">24.2 μg/mL</td></tr><tr><td colspan="3" rowspan="1">Triglycerides</td><td colspan="2" rowspan="1">3.35 mg/mL</td></tr><tr><td colspan="1" rowspan="2">Linearity</td><td colspan="5" rowspan="1">Criterion</td><td colspan="1" rowspan="2">Criterion                           ResultLinear throughout the measuring range     Linear withinof the kit (from LoQ to the highest        0.30 - 114.11calibrator)                          pg/mL</td></tr><tr><td colspan="5" rowspan="1">Linear throughout the measuring rangeof the kit (from LoQ to the highestcalibrator)</td><td colspan="1" rowspan="1">Linear within0.30 - 114.11pg/mL</td></tr><tr><td colspan="1" rowspan="7">Cross-reactivityDifferentmethodologyof cross-reactivitytesting</td><td colspan="6" rowspan="7">Pooled normal serumCompound                                                      CrossCross-reactantreactivitconc. (ng/mL)y(%)19-Nortestosterone                       8.62             0.06811-Ketotestosterone                       102              0020011beta-Hydroxytestosterone           14.1             0.029Androstenediol                              14.8              0.010Methyltestosterone                        96.5             0.017Androstenedione                          92.4             0.006Norethindrone                              1,056             0.0015α-Androstane-3α,17β-diol             1,076             0.0025β-Androstane-3,17-dione              1011              NDD5α-Androstane-3,17-dione              846              0.001Danazol                                       921              0.001Estradiol                                      946              0.001Progesterone                                956              0.001Deoxycorticosterone                      911               ND</td></tr><tr><td colspan="2" rowspan="2">Compound</td><td colspan="2" rowspan="1">Pooled normal serum</td></tr><tr><td colspan="1" rowspan="1">Cross-reactantconc. (ng/mL)</td><td colspan="1" rowspan="1">Crossreactivity(%)</td></tr><tr><td colspan="2" rowspan="4">19-Nortestosterone11-Ketotestosterone11beta-HydroxytestosteroneAndrostenediolMethyltestosteroneAndrostenedioneNorethindrone5α-Androstane-3α,17β-diol5β-Androstane-3,17-dione5α-Androstane-3,17-dioneDanazolEstradiolProgesteroneDeoxycorticosterone</td><td colspan="1" rowspan="4">8.6210214.114.896.592.41,0561,0761011846921946956911</td><td colspan="1" rowspan="1">0.06800200</td></tr><tr><td colspan="1" rowspan="3">0.0290.0100.0170.0060.0010.002NDD0.0010.0010.0010.001ND</td></tr><tr><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"></td></tr></table>

<table><tr><td rowspan=2 colspan=1>AndrosteroneEpiandosteroneDHEAEstriolEstroneCorticosteroneCortisolPregnenoloneDHTAndrostanediol GlucuronideDHEA-S5α -Androstan-3β, 17β diolrhSHBG</td><td rowspan=1 colspan=1>1,002943</td><td rowspan=2 colspan=1>NDNDNDNDNDNDNDND0.020NDND0.005ND</td></tr><tr><td rowspan=1 colspan=1>8968829139518579441681,03192298.010,407</td></tr></table>

ND = Non-Detectable $( < 0 . 1 \% )$

<table><tr><td rowspan="2">Compound</td><td colspan="2">Pooled depleted serum</td></tr><tr><td>Crossreactant conc. (ng/ml)</td><td>Cross reactivity (%)</td></tr><tr><td>19-Nortestosterone 11-Ketotestosterone</td><td>43.6 6.59</td><td>0.116 0.026</td></tr><tr><td>11beta-Hydroxytestosterone</td><td>2.62</td><td>0.029</td></tr><tr><td>Androstenediol</td><td>91.6</td><td>0.024</td></tr><tr><td>MethyItestosterone</td><td>11.1</td><td>0.005</td></tr><tr><td>Androstenedione</td><td>10.5</td><td>0.004</td></tr><tr><td>Norethindrone</td><td>40.0</td><td>0.002</td></tr><tr><td>5α -Androstane-3α,17β -diol</td><td>749</td><td>ND</td></tr><tr><td>5β -Androstane-3,17-dione</td><td>746</td><td>ND</td></tr><tr><td>5α -Androstane-3,17-dione</td><td>747</td><td>ND</td></tr><tr><td>Danazol</td><td>79.2</td><td>0.001</td></tr><tr><td>Estradiol</td><td>820</td><td>ND</td></tr><tr><td>Progesterone</td><td>8,330</td><td>ND</td></tr><tr><td>Deoxycorticosterone</td><td>7,681</td><td>ND</td></tr><tr><td>Androsterone</td><td>8,280</td><td>ND</td></tr><tr><td>Epiandosterone</td><td>7,634</td><td>ND</td></tr><tr><td>DHEA</td><td>8,362</td><td>ND</td></tr><tr><td>Estriol</td><td>8,981</td><td>ND</td></tr><tr><td>Estrone</td><td>8,442</td><td>ND</td></tr><tr><td>Corticosterone</td><td>7,197</td><td>ND</td></tr><tr><td>Cortisol</td><td>79,944</td><td>ND</td></tr><tr><td>Pregnenolone</td><td>83,919</td><td>ND</td></tr><tr><td>DHT</td><td>96.1</td><td>0.013</td></tr><tr><td>Androstanediol Glucuronide</td><td>8,111</td><td>ND</td></tr><tr><td>DHEA-S</td><td>89,418</td><td>ND</td></tr><tr><td>5α -Androstan-3β, 17β diol</td><td>43.1</td><td>0.001</td></tr><tr><td></td><td></td><td></td></tr><tr><td>rhSHBG</td><td>10,407</td><td>ND</td></tr></table>

ND = Non-Detectable $( < 0 . 1 \% )$

<table><tr><td>Method comparison</td><td>The current version Active® Free Testosterone RIA (Method A) was compared to previous version Active® Free Testosterone RIA (Method B):</td></tr></table>

<table><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range (pg/mL)</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R</td></tr><tr><td rowspan=1 colspan=1>278</td><td rowspan=1 colspan=1>0.26 - 101.21</td><td rowspan=1 colspan=1>1.0078</td><td rowspan=1 colspan=1>0.0759</td><td rowspan=1 colspan=1>0.9956</td></tr></table>

# 8. Performance Characteristics - Analytical Performance

Performance characteristics were measured to align product with current industry standards (data measured according to CLSI guidelines).

# 9. Conclusion:

The conclusions drawn from the non-clinical testing (discussed above) supports a substantial equivalence decision.

Verification of the changes does not raise any new items of safety and effectiveness.